What we are doing
At present, we are devoting much of our attention and
resources to help alleviate the spread of Covid-19 in the
We have recently partnered with Korean firm EuBiologics to
locally produce and distribute EuCorVac-19 which was
developed in the United States by POP Biotechnologies.
EuCorVac-19 is a genetic recombinant with a vaccine adjuvant
and has demonstrated excellent immunogenicity and safety.
Unlike other Covid-19 vaccines, it does not require
cryogenic temperature, making storage and distribution more
convenient as well as helping keep costs down.
We are in the early stages of constructing a state of the
art vaccine and biotech research and development facility,
that will allow us to produce 100 million doses of
EuCorVac-19 every year, as well as vaccines for other
diseases. We are targeting the facility to be operational by
the end of 2022. In the meantime, we are intend to import
EuCorVac-19 from Korea to help increase the Philippines’
supply of Covid-19 vaccine.